{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:16:30Z","timestamp":1787584590443,"version":"build-2736575974"},"reference-count":105,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Myasthenia gravis (MG) is an autoimmune disease in which autoantibodies target structures within the neuromuscular junction, affecting neuromuscular transmission. Muscle-specific tyrosine kinase receptor-associated MG (MuSK-MG) is a rare, often more severe, subtype of the disease with different pathogenesis and specific clinical features. It is characterized by a more severe clinical course, more frequent complications, and often inadequate response to treatment. Here, we review the current state of knowledge about potential pathomechanisms of the MuSK-MG and their therapeutic implications as well as ongoing research in this field, with reference to key points of immune-mediated processes involved in the background of myasthenia gravis.<\/jats:p>","DOI":"10.3390\/cells13060556","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T10:03:59Z","timestamp":1711101839000},"page":"556","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["MuSK Myasthenia Gravis\u2014Potential Pathomechanisms and Treatment Directed against Specific Targets"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9618-9308","authenticated-orcid":false,"given":"Edyta","family":"Dziadkowiak","sequence":"first","affiliation":[{"name":"Department of Neurology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6781-6758","authenticated-orcid":false,"given":"Dagmara","family":"Baczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-2803","authenticated-orcid":false,"given":"Marta","family":"Waliszewska-Pros\u00f3\u0142","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dresser, L., Wlodarski, R., Rezania, K., and Soliven, B. (2021). Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112235"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Dziadkowiak, E., Waliszewska-Pros\u00f3\u0142, M., Wieczorek, M., Bladowska, J., Budrewicz, S., and Ejma, M. (2021). Myasthenia Gravis-An Analysis of Multimodal Evoked Potentials. Brain Sci., 11.","DOI":"10.1038\/s41598-021-82281-6"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11940-014-0283-8","article-title":"Treatment of MuSK-Associated Myasthenia Gravis","volume":"16","author":"Yassin","year":"2014","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-Associated Myasthenia Gravis: Clinical Features and Management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: An update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mus.26404","article-title":"Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis","volume":"59","author":"Clifford","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3389\/fimmu.2020.00707","article-title":"Muscle-Specific Kinase Myasthenia Gravis","volume":"11","author":"Borges","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.autrev.2013.03.005","article-title":"Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis","volume":"12","author":"Mori","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lepore, E., Casola, I., Dobrowolny, G., and Musar\u00f2, A. (2019). Neuromuscular Junction as an Entity of Nerve-Muscle Communication. Cells, 8.","DOI":"10.3390\/cells8080906"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"610964","DOI":"10.3389\/fnmol.2020.610964","article-title":"The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing Synaptic Formation and Homeostasis","volume":"13","author":"Cossins","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.bbapap.2013.02.034","article-title":"Structure and activation of MuSK, a receptor tyrosine kinase central to neuromuscular junction formation","volume":"1834","author":"Hubbard","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"826.e1","DOI":"10.1016\/j.cell.2011.02.037","article-title":"SnapShot: Neuromuscular Junction","volume":"144","author":"Burden","year":"2011","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neuron.2008.10.006","article-title":"LRP4 serves as a coreceptor of agrin","volume":"60","author":"Zhang","year":"2008","journal-title":"Neuron"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","article-title":"Lrp4 is a receptor for Agrin and forms a complex with MuSK","volume":"135","author":"Kim","year":"2008","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Koneczny, I., and Herbst, R. (2019). Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture. Cells, 8.","DOI":"10.3390\/cells8070671"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"134676","DOI":"10.1016\/j.neulet.2019.134676","article-title":"MuSk function during health and disease","volume":"716","author":"Herbst","year":"2020","journal-title":"Neurosci. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1038\/srep06841","article-title":"HnRNP C, YB-1 and hnRNP L coordinately enhance skipping of human MUSK exon 10 to generate a Wnt-insensitive MuSK isoform","volume":"4","author":"Nasrin","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1111\/ejn.15382","article-title":"Timing and localization of myasthenia gravis-related gene expression","volume":"54","author":"Vergoossen","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0896-6273(95)90146-9","article-title":"Receptor tyrosine kinase specific for the skeletal muscle lineage: Expression in embryonic muscle, at the neuromuscular junction, and after injury","volume":"15","author":"Valenzuela","year":"1995","journal-title":"Neuron"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s004150050139","article-title":"Spatial and nonspatial memory involvement in myasthenia gravis","volume":"244","author":"Bohbot","year":"1997","journal-title":"J. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"40624","DOI":"10.1074\/jbc.M111.279307","article-title":"Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK)","volume":"286","author":"Zhang","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jmb.2006.09.019","article-title":"Crystal structure of the agrin-responsive immunoglobulin-like domains 1 and 2 of the receptor tyrosine kinase MuSK","volume":"364","author":"Stiegler","year":"2006","journal-title":"J. Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1126\/science.1127142","article-title":"The muscle protein Dok-7 is essential for neuromuscular synaptogenesis","volume":"312","author":"Okada","year":"2006","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.molcel.2010.06.007","article-title":"The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization","volume":"39","author":"Bergamin","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0969-2126(02)00814-6","article-title":"Crystal structure of the MuSK tyrosine kinase: Insights into receptor autoregulation","volume":"10","author":"Till","year":"2002","journal-title":"Structure"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1101\/gad.1977710","article-title":"Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L","volume":"24","author":"Hallock","year":"2010","journal-title":"Genes Dev."},{"key":"ref_29","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: Predominance of IgG subclasses 1 and 3","volume":"67","author":"Nielsen","year":"1987","journal-title":"Clin. Exp. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13928","DOI":"10.1038\/srep13928","article-title":"Collagen Q and anti-MuSK autoantibody competitively suppress agrin\/LRP4\/MuSK signaling","volume":"5","author":"Otsuka","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e200147","DOI":"10.1212\/NXI.0000000000200147","article-title":"IgG1-3 MuSK Antibodies Inhibit AChR Cluster Formation, Restored by SHP2 Inhibitor, Despite Normal MuSK, DOK7, or AChR Subunit Phosphorylation","volume":"10","author":"Cao","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Koneczny, I., Cossins, J., Waters, P., Beeson, D., and Vincent, A. (2013). MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080695"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e2020635118","DOI":"10.1073\/pnas.2020635118","article-title":"Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis","volume":"118","author":"Vergoossen","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/00365513.2023.2230550","article-title":"Galactosylation of serum immunoglobulin G in myasthenia gravis with different autoantibodies","volume":"83","author":"Hajdukovic","year":"2023","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ane.12951","article-title":"HLA and MuSK-positive myasthenia gravis: A systemic review and meta-analysis","volume":"138","author":"Hong","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.humimm.2013.08.271","article-title":"Association of HLA-DRB1\u221714, -DRB1\u221716 and -DQB1\u221705 with MuSK-myasthenia gravis in patients from Turkey","volume":"74","author":"Yilmaz","year":"2013","journal-title":"Hum. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jns.2016.02.031","article-title":"HLA-DRB1*14 and DQB1*05 are associated with Japanese anti-MuSK antibody-positive myasthenia gravis patients","volume":"363","author":"Kanai","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2013.12.005","article-title":"Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis","volume":"52","author":"Yi","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"109205","DOI":"10.1016\/j.intimp.2022.109205","article-title":"MicroRNA expression profiles of peripheral blood and mononuclear cells in myasthenia gravis: A systematic review","volume":"112","author":"Saghazadeh","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Beretta, F., Huang, Y.F., and Punga, A.R. (2022). Towards Personalized Medicine in Myasthenia Gravis: Role of Circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p. Cells, 11.","DOI":"10.3390\/cells11040740"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jns.2015.06.019","article-title":"Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients","volume":"356","author":"Punga","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jneuroim.2016.01.003","article-title":"Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis","volume":"292","author":"Punga","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1093\/hmg\/ddn251","article-title":"A mouse model for congenital myasthenic syndrome due to MuSK mutations reveals defects in structure and function of neuromuscular junctions","volume":"17","author":"Chevessier","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1093\/hmg\/ddh333","article-title":"MUSK, a new target for mutations causing congenital myasthenic syndrome","volume":"13","author":"Chevessier","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/hmg\/ddq110","article-title":"Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction","volume":"19","author":"Maselli","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_46","unstructured":"Ekstedt, J. (1964). Human single muscle fiber action potentials. Extracellular recording during voluntary and chemical activation. With some comments on end-plate physiology and on the fiber arrangement of the motor unit. Acta Physiol. Scand. Suppl."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jnnp.37.5.540","article-title":"Neuromuscular transmission in myasthenia gravis studied with single fibre electromyography","volume":"37","author":"Ekstedt","year":"1974","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1748-1716.1957.tb01411.x","article-title":"Multielectrode study of the territory of a motor unit","volume":"39","author":"Buchthal","year":"1957","journal-title":"Acta Physiol. Scand."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.clinph.2019.04.005","article-title":"Guidelines for single fiber EMG","volume":"130","author":"Sanders","year":"2019","journal-title":"Clin. Neurophysiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/mus.23638","article-title":"Single-fiber EMG and clinical correlation in Lambert-Eaton myasthenic syndrome","volume":"47","author":"Oh","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_51","first-page":"11","article-title":"Electrophysiological investigations in diagnosis and evaluation of ALS progress","volume":"35","year":"2001","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_52","first-page":"1830","article-title":"Single fiber electromyography in 78 patients with amyotrophic lateral sclerosis","volume":"117","author":"Cui","year":"2004","journal-title":"Chin. Med. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.clinph.2007.03.023","article-title":"Single-fiber electromyography in sporadic inclusion body myopathy","volume":"118","author":"Hatanaka","year":"2007","journal-title":"Clin. Neurophysiol."},{"key":"ref_54","first-page":"1","article-title":"Changes of single fiber electromyography in patients with inflammatory myopathies","volume":"20","author":"Jian","year":"2005","journal-title":"Chin. Med. Sci. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S1388-2457(00)00307-2","article-title":"SFEMG in ocular myasthenia gravis diagnosis","volume":"111","author":"Padua","year":"2000","journal-title":"Clin. Neurophysiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mus.20498","article-title":"Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis","volume":"33","author":"Oh","year":"2006","journal-title":"Muscle Nerve."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1468-1331.2006.01214.x","article-title":"Seronegative myasthenia gravis: Comparison of neurophysiological picture in MuSK+ and MuSK- patients","volume":"13","author":"Padua","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1007\/s00415-022-10986-3","article-title":"Bedside and laboratory diagnostic testing in myasthenia","volume":"269","author":"Yoganathan","year":"2022","journal-title":"J. Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.25214","article-title":"Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis","volume":"55","author":"Abraham","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/jnnp.2004.043125","article-title":"Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis","volume":"76","author":"Nemoto","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1179\/1743132814Y.0000000387","article-title":"Electrophysiological profile of the patients with MuSK positive myasthenia gravis","volume":"36","author":"Nikolic","year":"2014","journal-title":"Neurol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0404.2006.00721.x","article-title":"Anti-MuSK-positive myasthenia gravis: Neuromuscular transmission failure in facial and limb muscles","volume":"115","author":"Kuwabara","year":"2007","journal-title":"Acta Neurol. Scand."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/mus.20491","article-title":"Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis","volume":"33","author":"Farrugia","year":"2006","journal-title":"Muscle Nerve"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.clinph.2006.03.028","article-title":"Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes","volume":"117","author":"Ahlqvist","year":"2006","journal-title":"Clin. Neurophysiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s13760-018-0915-y","article-title":"Quality of life in patients with MuSK positive myasthenia gravis","volume":"118","author":"Stankovic","year":"2018","journal-title":"Acta Neurol. Belg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1072861","DOI":"10.3389\/fneur.2022.1072861","article-title":"Reduced quality of life in myasthenia gravis patients: A study on 185 patients from China","volume":"13","author":"Wu","year":"2023","journal-title":"Front. Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: Taking the patient\u2019s perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"120268","DOI":"10.1016\/j.jns.2022.120268","article-title":"The humanistic burden of myasthenia gravis: A systematic literature review","volume":"437","author":"Gelinas","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Waliszewska-Pros\u00f3\u0142, M., and Ejma, M. (2022). Hashimoto Encephalopathy-Still More Questions than Answers. Cells, 11.","DOI":"10.3390\/cells11182873"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Dziadkowiak, E., Waliszewska-Pros\u00f3\u0142, M., Nowakowska-Kotas, M., Budrewicz, S., Koszewicz, Z., and Koszewicz, M. (2021). Pathophysiology of the Different Clinical Phenotypes of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010179"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s13311-022-01210-1","article-title":"Autoimmune Neurological Disorders with IgG4 Antibodies: A Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies","volume":"19","author":"Dalakas","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrneurol.2014.260","article-title":"Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders","volume":"11","author":"Stathopoulos","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1212\/NXI.0000000000001116","article-title":"IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies","volume":"9","author":"Dalakas","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: A case series, characterisation of the antigen, and post-mortem study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000503967","article-title":"Basic Research and Clinical Reports Associated with Low Serum IgG4 Concentrations","volume":"181","author":"Tian","year":"2020","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinph.2021.04.019","article-title":"Cholinergic hyperactivity in patients with myasthenia gravis with MuSK antibodies: A neurophysiological study","volume":"132","author":"Modoni","year":"2021","journal-title":"Clin. Neurophysiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG","volume":"4","author":"Huda","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.0000000000002466","article-title":"3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies","volume":"86","author":"Evoli","year":"2016","journal-title":"Neurology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.clineuro.2012.06.038","article-title":"Can a rare form of myasthenia gravis shed additional light on disease mechanisms?","volume":"115","author":"Haran","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1007\/s00415-021-10603-9","article-title":"MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation","volume":"268","author":"Stetefeld","year":"2021","journal-title":"J. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/WCO.0b013e32833c0982","article-title":"Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis","volume":"23","author":"Guptill","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","article-title":"Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase","volume":"12","author":"Evoli","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1275533","DOI":"10.3389\/fneur.2023.1275533","article-title":"Rituximab treatment in myasthenia gravis","volume":"14","year":"2023","journal-title":"Front. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B Cells and Plasma Cells in Autoimmune Diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/nyas.13561","article-title":"IgG4-mediated autoimmune diseases: A niche of antibody-mediated disorders","volume":"1413","author":"Huijbers","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Tejerina, D., Sotoca, J., Llaurado, A., L\u00f3pez-Diego, V., Juntas-Morales, R., and Salvado, M. (2022). New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies. J. Clin. Med., 11.","DOI":"10.3390\/jcm11216394"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/WCO.0000000000000596","article-title":"Myasthenia gravis: From autoantibodies to therapy","volume":"31","author":"Mantegazza","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1212757","DOI":"10.3389\/fimmu.2023.1212757","article-title":"Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease","volume":"14","author":"Vakrakou","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/nyas.13535","article-title":"Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis","volume":"1412","author":"Stathopoulos","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/14712598.2023.2296126","article-title":"An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis","volume":"23","author":"Matic","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Keller, C.W., Pawlitzki, M., Wiendl, H., and L\u00fcnemann, J.D. (2021). Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115755"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement Inhibitor Therapy for Myasthenia Gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","article-title":"Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: A Review in Generalized Myasthenia Gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285617721093","article-title":"Bortezomib in severe MuSK-antibody positive myasthenia gravis: First clinical experience","volume":"10","author":"Ellrichmann","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e000241","DOI":"10.1136\/bmjmed-2022-000241","article-title":"New and emerging treatments for myasthenia gravis","volume":"2","author":"Patel","year":"2023","journal-title":"BMJ Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.nmd.2008.06.368","article-title":"Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor","volume":"18","author":"Maggi","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00281-021-00842-3","article-title":"Thymus and autoimmunity","volume":"43","author":"Marx","year":"2021","journal-title":"Semin. Immunopathol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/6\/556\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:17:40Z","timestamp":1760105860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/6\/556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":105,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cells13060556"],"URL":"https:\/\/doi.org\/10.3390\/cells13060556","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]}}}